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OBJECTIVES: New treatment options for advanced NSCLC can offer improved sur-
vival over standard chemotherapy, but should also offer value for money. Bevaci-
zumab, a humanised monoclonal antibody (MAb) against VEGF, plus chemotherapy 
increases overall survival and progression-free-survival (PFS) in advanced NSCLC 
patients versus chemotherapy alone. Cetuximab, a MAb targeting EGFR, plus chemo-
therapy has also improved outcomes in these patients. This study compared the costs 
and life-years gained when treating patients with BCG or CVC in Sweden. METHODS: 
A Markov model is used to compare total health care costs associated with treating 
advanced or recurrent NSCLC with BCG or CVC. The model assumes patients move 
from pre-progressive to a progressed disease state to death, according to a set of 
transition probabilities derived from an indirect comparison (IC) of BCG and CVC 
efﬁcacy in terms of PFS using respective pivotal trials data and appropriate IC meth-
odology. Cost data were derived from local sources in Sweden. Drug costs assumed 
chemotherapy was given up to 6 cycles, cetuximab was administered initially at 
400 mg/m2 (then 250 mg/m2) weekly until progression and bevacizumab 7.5 mg/kg 
every third week was administered until progression. The model estimated average 
health care costs per patient treated with BCG or CVC. Sensitivity analyses were run 
with different subpopulation characteristics. RESULTS: The mean life-years in the 
model are 1.515 for BCG and 1.379 for CVC. The mean total cost of BCG treatment 
(SEK265,919) is lower than CVC (SEK336,033). Hence, adding bevacizumab to 
 chemotherapy (SEK164,139) was less costly than adding cetuximab to chemotherapy 
(SEK242,681). Administration costs are lower for bevacizumab (SEK4,545) than 
cetuximab (SEK28,627). CONCLUSIONS: This comparison shows that therapy using 
bevacizumab is less costly and adds more life-years than therapy using cetuximab. 
When choosing between bevacizumab abd cetuximab, bevacizumab offers a cost-
saving approach to improving outcomes in patients with advanced NSCLC.
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OBJECTIVES: In 2008, Health Canada approved an expanded indication for bort-
ezomib in untreated multiple myeloma (MM) patients who are unsuitable for stem 
cell transplant. Treatment options for these patients include melphalan and prednisone 
(MP) or MP and thalidomide (MPT). The objective was to conduct a cost-effectiveness 
analysis of bortezomib and MP (VMP) compared to MP and MPT. METHODS: The 
VISTA study provided clinical evidence to support VMP versus MP. This study was 
a large, international, randomized study showing the clinical beneﬁts of VMP over 
MP. There were no studies that directly compared VMP to MPT. A previously pub-
lished comparison of MPT versus MP studies was updated to include more recent 
MPT studies, allowing for VMP to be compared indirectly to MPT. The economic 
model projected overall survival over a 10-year horizon for VMP, MP and MPT. The 
provincial Ministry of Health perspective was used. Observed overall survival data (at 
least 3-years) of VMP, MP and MPT was used from the relevant studies, and projected 
to 10-years based on information from similar type studies and survival hazard ratios. 
The survival projection was conservative for VMP as although the VMP and MP sur-
vival curves were diverging at 36-months, the projected VMP and MP survival curves 
remained parallel. Resource use included costs of drugs, outpatient cancer clinic, 
managing adverse events, supportive care and a subsequent line of MM treatment. 
RESULTS: The discounted QALY was 3.51 (VMP), 2.84 (MP) and 3.29 (MPT). The 
total cost was CAN $59,117 (VMP), $27,026 (MP), and $52,225 (MPT). The ICER 
of VMP versus MP was $48,294 and $31,975 for VMP versus MPT. The parameter 
that was most inﬂuential in the sensitivity analysis was the survival difference. CON-
CLUSIONS: The new VMP regimen indicates good value for money, and is being 
adopted for funding by public cancer agencies in Canada.
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OBJECTIVES: The objective of the present study is to evaluate the cost-effectiveness 
of HPV vaccination alongside cervical cancer screening programme in Slovenia. 
METHODS: A Markov model representing natural history of HPV infection was 
adapted to Slovenian context. The model followed a cohort of 12 year-old girls until 
the age of 85 years. Two strategies were compared: HPV vaccination alongside con-
ventional cytological screening versus screening alone. The analysis considered the 
beneﬁts of HPV vaccination on the incidence of cervical cancer and precancerous 
cervical lesions. The analysis was performed from the health care payer perspective. 
RESULTS: Vaccination with screening compared to screening alone was associated 
with an incremental cost-effectiveness ratio (ICER) of a7568 per quality adjusted 
life-year (QALY) gained and a13,494 per life-year gained (LYG). Sensitivity analyses 
demonstrated that the ICER was robust to parameters but was most sensitive to the 
need for booster dose and to different values of discount rates. CONCLUSIONS: 
According to the cost-effectiveness thresholds used in the developed countries, 
HPV vaccine to current screening programme in Slovenia can be regarded as 
cost-effective.
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OBJECTIVES: To determine the incremental cost-effectiveness of histamine dihydro-
chloride  low dose interleukin-2 vs standard of care (maintenance therapy) in patients 
experiencing their ﬁrst complete remission from AML. METHODS: Data from a 
multi-national phase-III clinical trial (129 received drug and 132 standard care) pro-
vided rates for remission (leukemia free survival), relapse and death at 5 years. From 
the payor perspective, resources consumed (concomitant medications, blood products, 
emergency room visits, physician visits) were tabulated by treatment arm and assigned 
a unit cost from UK sources, discounted at 5%. The cost of relapse was estimated 
from the literature as patients from the clinical trial were not followed once in relapse. 
The cost of histamine dihydrochloride (used in conjunction with low dose interleukin-
2) was not included in the analysis as no pricing has been established to date. Esti-
mated drug cost was computed based on ICERs using £30K, £35K and £40K ceiling. 
RESULTS: Five-year Leukemia Free Survival (LFS) for drug and standard of care was 
2.23 vs 1.75 years (P  0.02), respectively. Mean cost/patient treated was £40,209 
with treatment and £41,702 with standard care, which includes IL-2 cost (£3,600) for 
the complete 10 cycles. To compute the maximum cost of histamine dihydrochloride, 
ICERs were computed with £30K, £35K and £40K ceilings, to estimate acquisition 
costs for patients who receive all 10 treatment cycles. Acquisition costs were £24,265, 
£27,928 and, £31,592, respectively. CONCLUSIONS: Maintenance therapy with 
histamine dihydrochloride  low dose interleukin-2 vs standard care for patients in 
their ﬁrst complete remission from AML provides approximately 0.5 years more of 
LFS and can be done cost-effectively if acquisition costs are below reasonable thresh-
olds. Increased LFS also reduces relapse rates, further contributing to cost savings.
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OBJECTIVES: To evaluate the cost-effectiveness of docetaxel versus a once weekly 
paclitaxel regimen in patients with metastatic breast cancer previously treated with 
anthracycline from the Spanish National Health Service perspective. METHODS: A 
Markov model with 21 days-cycle duration was developed to estimate the total treat-
ment related costs and clinical beneﬁts over 5 years of docetaxel (100 mg/m 2) every 
21 days and paclitaxel (80 mg/m 2) once weekly regimen. Individual patient data were 
obtained from the TAX 311 clinical trial. Utilities values were obtained from published 
literature and unitary costs (a2009) from a Spanish health cost database and the 
Spanish Catalogue of Medicines. Cost and beneﬁts (life years gained, LYG and quality-
adjusted life years, QALY) were discounted at 3%. Probabilistic and deterministic 
sensitivity analyses were conducted. RESULTS: Docetaxel yields higher health beneﬁts 
(1.83LYGs and 1.08 QALYs) than paclitaxel (1.46 LYGs and 0.84 QALYs). Global 
costs (treatment, concomitant medication, adverse events management, progression, 
best supportive care and end of life phase) per patient were a20,052 and a19,982 with 
docetaxel and paclitaxel, respectively. Incremental cost-effectiveness ratio (ICER) of 
docetaxel versus paclitaxel was a190/LYG and a295/QALY. Based on a a30,000/LYG 
or QALY threshold, docetaxel, compared with paclitaxel, has a 99% probability of 
being cost-effective. The ICER was mostly sensitive to the hazard ratio (when was 
varied from 1.46 to 1.09; a3517/QALY), the discount over the ex-lab price of Taxol® 
(75%; a6396/QALY) and the G-CSF prophylactic treatment (when administered in 
60% of cycles instead 100%; cost saving). Variations of other inputs as time horizon 
(3–10 years), discount rate (0–5%) or adverse event cost (o 25%) were not shown 
relevant inﬂuence in the results. CONCLUSIONS: Compared to once weekly paclit-
axel, docetaxel therapy is a cost-effective option for treatment in metastatic breast 
cancer patients.
